know that Black and Hispanic patients with acute myeloid leukemia have higher mortality rates that are reliably predicted by census tract measures and treatment patterns. 9 A strictly utilitarian approach to allocation of vincristine based only on
Search Results
Chemotherapeutic Shortages: How Do We Prioritize?
Emily A. Harlan and Andrew G. Shuman
NCCN News
following topics: Acute Myeloid Leukemia (AML) Breast Cancer Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Colon Cancer Gastric Cancer Hairy Cell Leukemia Head and Neck Cancers Hodgkin Lymphoma Melanoma (Cutaneous) Multiple Myeloma Non
The NCCN 2020 Virtual Congress: Hematologic Malignancies
Robert W. Carlson
therapeutic options in acute lymphoblastic leukemia, evolving concepts in the diagnosis and staging of multiple myeloma, advances in acute myeloid leukemia management, and emerging therapeutic options in acute lymphoblastic leukemia, among others. The
NCCN Conference Addressed Value-Based Healthcare Models, Payer Perspectives, New NCCN Guidelines, and Other Updates in Cancer Care
following types of cancer: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Breast Chronic Myeloid Leukemia Colorectal Head and Neck Kidney Lung Melanoma Multiple Myeloma Ovarian Prostate Urothelial Carcinoma New
NCCN Guidelines Raise Standards for Cancer Care Worldwide by Exceeding 10 Million Downloads in 2018 — Up 26% Over 2017
past year included updates to most patient guidelines, plus new booklets for: Acute Myeloid Leukemia Liver, Gallbladder, and Bile Duct (Hepatobiliary) Cancers Uterine (Endometrial) Cancer Neuroendocrine Tumors Oral Cancers Looking Ahead In the year
Eligibility Criteria for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Abraham S. Kanate, Miguel-Angel Perales, and Mehdi Hamadani
appropriate. For example, allo-HCT may be considered the standard of care for some diseases (eg, acute myeloid leukemia [AML] or myelodysplastic syndromes [MDS]), whereas in others it may be considered developmental and ideally offered in the context of a
Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults: Geriatric Principles in the Transplant Clinic
Tanya M. Wildes, Derek L. Stirewalt, Bruno Medeiros, and Arti Hurria
-HCT to be performed in patients previously considered ineligible. Although most studies comparing the results of myeloablative with reduced-intensity conditioning are limited to patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS
The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders
Rafael Bejar and Peter L. Greenberg
mutations contribute to the development and clinical outcomes of MDS, including their propensity to progress to more aggressive stages, such as acute myeloid leukemia (AML). Despite these findings, ambiguity remains about how best to use somatic mutations to
Clinical Availability of ATRA for Patients With Suspected Acute Promyelocytic Leukemia: Why Guidelines May Not Be Followed
Marcus J. Geer, Charles E. Foucar, Sumana Devata, Lydia Benitez, Anthony J. Perissinotti, Bernard L. Marini, and Dale Bixby
patients with APL. 1 SEER-17 data from 2001 to 2007 showed that APL represented 7.4% of all patients diagnosed with acute myeloid leukemia (AML), with an incidence rate of 2.7%. 2 Although the 5-year survival is higher in APL than in other AML subtypes
NCCN News
receive up to $150,000 in funding to study ways to improve care and help find cures for people with breast, colorectal, pancreatic, and small cell lung cancer, as well as pediatric acute myeloid leukemia. The NCCN Oncology Research Program (ORP) managed
